Updates

CentralNIC

February 2022

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

CNIC’s performance continues to shoot the lights out and the shares shot back to their highs after it said organic growth accelerated during Q4. It now expects organic revenue growth of 37% for the full year ended December (up from +29% recorded for the first nine months). In particular, CentralNic’s Online Marketing division’s PubTONIC product is worth a mention. This is seeing huge demand. The IP for PubTONIC was developed in-house and parts of it are patented. The platform allows ads to be placed on any platform - Facebook, Taboola, OutBrain, Bing, TikTok - extending the reach of any walled garden advertising platform to reach customers on other walled garden platforms. It forms the basis of a traffic marketplace that will be able to ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Xaar - Surprise profit in H2 21

Ramsdens - FX volumes climb as travel resumes

CentralNIC (May 2023)

CentralNic (January 2023)

CentralNic (October 2022)

CentralNic (March 2022)

CentralNic - Year-to-date organic growth now reaching a record 29%; 268p broker target (November 2021)

CentralNic (October 2021)

CentralNic (July 2021)

CentralNic (February 2021)

CentralNIC (January 2021)

CentralNIC - 20% eps accretive acquisition of Codewise (October 2020)

CentralNic (April 2020)

CentralNic (February 2020)

CentralNic - 44% eps accretive deal (December 2019)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X